en · de · es
nad-notes.peptides6155.com › Data › Sr9009 Identity And Mechanism — Background and Details

Sr9009 Identity And Mechanism — Background and Details

By Editorial Desk · published 2026-03-31 · last reviewed 2026-05-07 · Data

anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-05-07. Where a claim depends on a specific study, the study is described rather than over-claimed.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Regulation, Testing, and Storage

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also marketed informally as Stenabolic
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ
Molecular formulaC24H30ClN3O4SApproximate molecular weight 492 g/mol
CAS Registry Number1379686-30-2Identifier for the parent compound
Regulatory statusNot approved for human useProhibited in sport by WADA

Handling Storage and Quality Control

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Related pages on this site

Background and Receptor Pharmacology

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Notes from published material

== Major leagues == Epstein was first brought up for six games by the Baltimore Orioles in 1966, at the age of 23. After the Orioles tried in vain to convert him to the outfield (they already had Boog Powell at first base), they demoted him to Rochester again. The outspoken Epstein refused to report, going home to California and continuing his schooling instead. He was traded along with Frank Bertaina from the Orioles to the Washington Senators for Pete Richert on 29 May 1967, going from one of the best organizations in baseball to one of the worst. Later that season, in his first at-bat against the Orioles, Epstein hit a grand slam. In 1968 he was fourth in the league in getting hit by pitches HBP (9). In 1969 with the Senators, in only 403 at bats Epstein hit 30 home runs (ninth in the American League), had 85 runs batted in (RBIs), and hit for a .278 batting average (and .347 with runners in scoring position) with an excellent .414 on-base percentage and .551 slugging percentage. He was fourth in the league in hit by pitch (10), and he hit a home run every 13.4 at bats. He was 25th in voting for the American League MVP. This was also the only year in which the reconstituted Senators (now the Texas Rangers) finished above .500. In 1970, he was second in the league in being hit by a pitch (13), while hitting 20 home runs, and leading all AL first basemen in range factor (10.08). In 1969-70, he was managed by Hall of Fame hitting great Ted Williams.

=== pH and bile tolerance === Testing of L. fermentum against different pH concentration solutions revealed that it has a strong pH tolerance by its ability to grow and survive a few hours after being incubated in a 3-pH level solution. Strains of L. fermentum have also been tested in different bile concentrations and demonstrated to have good bile tolerance when incubated with 3 g L-1 of bile salt. L. fermentum has been found to survive in these conditions further supporting the idea that it can act as a probiotic.

Depending on the column size, CIM monolithic columns are primarily used for the purification or analysis of large biomolecules which are being used for cancer gene therapy, treatment of viral infectious diseases and treatment of genetic diseases. Some types of molecules that can be successfully purified using CIM columns are pDNA, IgM, inter-alpha inhibitors, virus like particles, and diverse viruses; adenoviruses, bacteriophages, feline calicivirus, hepatitis A, lentivirus, influenza A and B, rabies virus, rotavirus, tomato and pepino mosaic virus. Since 2004, BIA Separations has organized and hosted the Monolith Summer School and Symposium (MSS) which takes place every 2 years. MSS was established as there were no dedicated conferences to this technology and to bring together the top international scientists and researchers in the area of monolith chromatography to share their experiences and innovative applications. BIA Separations home page Monolith Events

The orthologues and homologues of TMEM261 are limited to vertebrates, its oldest homologue dates to that of the cartilaginous fishes which diverged from Homo sapiens 462.5 million years ago. The protein primary structure of TMEM261 shows higher overall conservation in mammals, however high conservation of the domain of unknown function (DUF4536) to the C-terminus region is seen in all orthologues, including distant homologues. The protein structure of TMEM261 shows conservation across most orthologues. TMEM261 has no known paralogs. PubMed NCBI gene record GeneCards UCSC Genome Browser Expasy Bioinformatics Resource Portal SDSC Biology Workbench Uniprot HUGO Archived 2015-09-24 at the Wayback Machine

Sources: en.wikipedia.org

Further detail

=== SCIRI === The organization was formed in Iran in 1982 as the military wing of the Supreme Council for Islamic Revolution in Iraq. It was based in Iran for two decades during the rule of Saddam Hussein and led by Iranian officers. It consisted of several thousand Iraqi exiles, refugees, and Iraqi Army defectors who fought alongside Iranian troops in the Iran–Iraq War. The group was armed and directed by Iran. They briefly returned to Iraq in 1991 during the 1991 Iraqi uprising to fight against the government of Saddam Hussein, focusing on the Shia holy cities of Najaf and Karbala. They retreated into Iran after the uprising was brutally crushed by the Ba'athist regime. In 1995, during the Iraqi Kurdish Civil War, Iran deployed 5,000 Badr fighters to Iraqi Kurdistan to support the PUK forces.

Models of ideal materials have shown that this zone of plasticity is centered at the crack tip. This equation gives the approximate ideal radius of the plastic zone deformation beyond the crack tip, which is useful to many structural scientists because it gives a good estimate of how the material behaves when subjected to stress. In the above equation, the parameters of the stress intensity factor and indicator of material toughness,

Extracting oil (or "bitumen") from oil/tar sand and oil shale deposits requires mining the sand or shale and heating it in a vessel or retort, or using "in-situ" methods of injecting heated liquids into the deposit and then pumping the liquid back out saturated with oil.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Is SR9009 approved for human use?

No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.

Why is SR9009 banned in sport?

The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.

Is SR9009 legal?

Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.

Network